Response to: Interference of daratumumab on the serum protein electrophoresis
- 1 January 2017
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 55 (2), e29-e30
- https://doi.org/10.1515/cclm-2016-1026
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Quantification of daratumumab in the serum protein electrophoresiscclm, 2017
- Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assayClinical Biochemistry, 2016
- Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interferencecclm, 2016
- Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) TreatmentClinical Lymphoma Myeloma and Leukemia, 2015
- Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal GammopathiesClinical Chemistry, 2011
- Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis TestsClinical Chemistry, 2010
- The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratiosBlood, 2009
- International uniform response criteria for multiple myelomaLeukemia, 2006